IDO2 has been reported to be overexpressed along with IDO1 in pancreatic cancer (22, 23), and in basal cell skin carcinomas, where its expression appears to be driven by the T-cell-attracting chemokine CXCL11 (16), but neither the extent of IDO2 expression nor knowledge of its regulatory mechanisms in cancer settings are as widely described as IDO1 as yet. Here, IDO2 is linked to pancreatic neoplasm.